

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



07 May 2026

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Credit Rating

This is to inform that today CRISIL Ratings Limited (“CRISIL”) has reaffirmed the rating on the long-term bank facilities for Sun Pharmaceutical Industries Limited (“Sun Pharma”), at ‘Crisil AAA’ and short-term bank facilities and commercial paper at ‘Crisil A1+’.

CRISIL has placed the ‘Crisil AAA’ rating on the long-term bank facilities on ‘Rating Watch with Developing Implications’. This rating action follows Sun Pharma’s announcement dated 27 April 2026, about signing a definitive agreement to acquire Organon & Co. (“Announcement”)

CRISIL has further communicated that it will remove the rating from watch and announce its final rating action post a comprehensive assessment of this acquisition.

This is to also inform that ICRA Limited has reaffirmed the rating on the long-term bank facilities for Sun Pharma, at ‘[ICRA]AAA(Stable)’ and short-term bank facilities and commercial paper at ‘[ICRA]A1+’ after taking note of the Announcement.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983